A prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.

• Conditions: adenocarcinoma of the colon; colon cancer; 10017990

• Registration Number: NL-OMON31942
• Lead Sponsor: Agendia B.V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- > 18
- adenocarcinoma of the colon
- stage II (1-III) planned to be treated with radical surgery

Exclusion Criteria

- prior malignancy with the exception of basal cell carcinoma or cervical dysplasia
- any neo-adjuvant therapy
- synchronous tumors

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• Endpoint: risk assessment by Physician (based on local protocol) in<br /><br>comparison with ColoPrint result<br /><br>• Endpoint: relapse or 3 years disease-free survival (DFS)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-</p><br>